![Stefan Mazgareanu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan Mazgareanu
Profile
Stefan Mazgareanu worked as a VP-Project Management & Preclinical Research at IDEA AG and as a Chief Operating Officer & Senior Vice President at Cardiorentis AG.
Former positions of Stefan Mazgareanu
Companies | Position | End |
---|---|---|
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Chief Operating Officer | 01/06/2016 |
IDEA AG
![]() IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
IDEA AG
![]() IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Health Technology |
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Stefan Mazgareanu